Teva has described its proposed generic version of Eli Lilly’s Forteo (teriparatide) as “the most important” potential US generic launch this year, “one which would be a significant contributor to our sales in 2022,” despite development partner Antares Pharma electing not to include any US teriparatide revenues in its 2022 annual financial guidance.
Low-competition, high-margin approvals and launches in the US are crucial to Teva’s prospects this year, one which the Israeli giant...







